- Home
- CVM vs MBRX Comparison
CVM vs MBRX Comparison
Compare CVM & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- MBRX
- Stock Information
- Founded
- CVM 1983
- MBRX 2015
- Country
- CVM United States
- MBRX United States
- Employees
- CVM N/A
- MBRX N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- MBRX Health Care
- Exchange
- CVM Nasdaq
- MBRX Nasdaq
- Market Cap
- CVM 11.8M
- MBRX 12.9M
- IPO Year
- CVM 1987
- MBRX 2016
- Fundamental
- Price
- CVM $3.46
- MBRX $0.55
- Analyst Decision
- CVM
- MBRX Strong Buy
- Analyst Count
- CVM 0
- MBRX 3
- Target Price
- CVM N/A
- MBRX $5.33
- AVG Volume (30 Days)
- CVM 1.6M
- MBRX 11.7M
- Earning Date
- CVM 08-14-2025
- MBRX 08-13-2025
- Dividend Yield
- CVM N/A
- MBRX N/A
- EPS Growth
- CVM N/A
- MBRX N/A
- EPS
- CVM N/A
- MBRX N/A
- Revenue
- CVM N/A
- MBRX N/A
- Revenue This Year
- CVM N/A
- MBRX N/A
- Revenue Next Year
- CVM N/A
- MBRX N/A
- P/E Ratio
- CVM N/A
- MBRX N/A
- Revenue Growth
- CVM N/A
- MBRX N/A
- 52 Week Low
- CVM $1.98
- MBRX $0.25
- 52 Week High
- CVM $66.60
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- MBRX 51.51
- Support Level
- CVM $2.24
- MBRX $0.33
- Resistance Level
- CVM $2.71
- MBRX $0.70
- Average True Range (ATR)
- CVM 0.51
- MBRX 0.07
- MACD
- CVM 0.25
- MBRX 0.04
- Stochastic Oscillator
- CVM 25.61
- MBRX 66.24
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.